Recombinant Llama VHH-Human IgG Antibody for high-sensitivity SARS-CoV-2 spike protein detection assays.
Catalog No. C19S1-641HL
|Catalog No.||Pack Size||Price (USD)|
The severe acute respiratory syndrome related novel coronavirus SARS-CoV-2 has caused the pandemic of the respiratory diseases (COVID-19) around the world in 2020 (1). The spike glycoprotein (S) of coronavirus belongs to the type I transmembrane protein containing two subunits, S1 and S2 (2), which is also known to be the key component to bind with host cells through the interaction with angiotensin-converting enzyme 2 (ACE2) (3). A receptor binding domain (RBD) of S1 can recognize the cell surface receptor and the mutation of RBD could cause higher motility rate (3).
1. Zhou P, et al: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270-89.
2. Xiao X, et al: The SARS-CoV S glycoprotein. Cell Mol Life Sci. 2004, 61 (19-20): 2428-30.
3. Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. doi: https://doi.org/10.1101/2020.02.19.956235
Recognizes the 2019-nCoV Spike protein
Llama VHH-Human IgG Fc
Anti 2019-nCoV Spike Protein single-chain Antibody
Storage, Stability, and Shipping:
1yr at –20oC from date of shipment
Assay Data :
Sample Activity Plot. For specific information on a given lot, see the related technical data sheet.
Assay Data :
Binding of Anti 2019-nCoV Spike Protein Llama heavy-chain (C19S1-641HL) to 2019-nCoV RBD (C19SD-G241H) determined by ELISA.
There are no related publications available for this product.